XOMA Royalty (XOMA) EPS (Weighted Average and Diluted) (2010 - 2026)
XOMA Royalty's (XOMA) quarterly EPS (Weighted Average and Diluted) came in at $0.17 in Q1 2026, up 183.33% year-on-year from $0.06 in Q1 2025, and down 34.62% quarter-over-quarter from $0.26 in Q4 2025.
XOMA Royalty (XOMA) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed EPS (Weighted Average and Diluted) across 17 years of filings, most recently posting $0.17 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.17, up 183.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.57 (up 237.72% YoY), and the FY2025 annual result was $1.46, up 188.48% from the prior year.
- EPS (Weighted Average and Diluted) came in at $0.17 for Q1 2026 at XOMA Royalty, down from $0.26 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.84 in Q2 2024 to a low of -$1.87 in Q4 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.48 (2022), against an average of -$0.38.
- Across the five-year window, EPS (Weighted Average and Diluted) slumped 206.25% in 2023 and soared 242.37% in 2024, its largest moves.
- XOMA Royalty's EPS (Weighted Average and Diluted) stood at -$0.64 in 2022, then tumbled by 192.19% to -$1.87 in 2023, then soared by 75.94% to -$0.45 in 2024, then surged by 157.78% to $0.26 in 2025, then tumbled by 34.62% to $0.17 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.17 (Q1 2026), $0.26 (Q4 2025), and $0.7 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 0.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.17 |
| Dec 31, 2025 | 0.26 |
| Sep 30, 2025 | 0.70 |
| Jun 30, 2025 | 0.44 |
| Mar 31, 2025 | 0.06 |
| Dec 31, 2024 | -0.45 |
| Sep 30, 2024 | -1.59 |
| Jun 30, 2024 | 0.84 |
| Mar 31, 2024 | -0.86 |
| Dec 31, 2023 | -1.87 |
| Sep 30, 2023 | -0.60 |
| Jun 30, 2023 | -0.59 |
| Mar 31, 2023 | -0.98 |
| Dec 31, 2022 | -0.64 |
| Sep 30, 2022 | -0.48 |
| Jun 30, 2022 | -0.53 |
| Mar 31, 2022 | -0.32 |
| Dec 31, 2021 | 2.18 |
| Sep 30, 2021 | -0.51 |
| Jun 30, 2021 | -0.31 |